A Randomized Controlled Trial Comparing Underwater Versus Conventional Preventive Coagulation for Intraprocedural Vessel Management During Peroral Endoscopic Myotomy (POEM)
POEM
1 other identifier
observational
120
1 country
1
Brief Summary
Peroral Endoscopic Myotomy (POEM) has become an established, minimally invasive therapy for achalasia and esophageal motility disorders. Submucosal tunnelling is a critical phase of POEM and requires meticulous haemostasis to avoid bleeding, loss of orientation, reduced visibility, and prolonged procedural time. The current standard method of vessel coagulation during POEM involves conventional coagulation under CO₂ insufflation using the hybrid knife (HK). However, this approach can require additional hemostatic devices-most commonly coagulation forceps-particularly when dealing with large-calibre vessels or resistant bleeding. A novel technique-underwater preventive coagulation-leverages water as a conductive medium. Preliminary evidence suggests that:
- electrosurgical current in water is focalized at the interface of the vessel,
- allowing a soft sealing of the vessel wall,
- reducing the risk of vessel rupture or unintended deep thermal injury,
- and potentially eliminating the need to convert to coagulation forceps. Pilot data from our center demonstrate that underwater prophylactic sealing of large vessels during POEM is feasible, safe, and associated with markedly reduced need for rescue coagulation forceps. The technique is already used in practice but lacks systematic evidence from prospective randomized trials. This study is designed to provide high-quality evidence on whether underwater vessel coagulation improves haemostatic efficiency, reduces intra-procedural bleeding, and minimizes device changes during POEM. All POEM procedures will be performed under general anesthesia in the supine position using Fujifilm high-definition gastroscopes with a 2.8 mm channel and transparent distal cap. Steps (Both Arms)
- Identify the esophagogastric junction (EGJ).
- Inject saline + methylene blue submucosally.
- Create a 2 cm mucosal incision at 5-6 o'clock position, 10 cm above EGJ.
- Enter the submucosal space.
- Perform submucosal tunnelling down to EGJ and 2-3 cm into cardia.
- Perform vessel haemostasis according to group allocation:
- Underwater coagulation (intervention)
- CO₂-based conventional coagulation (control)
- Perform circular myotomy (with occasional full-thickness myotomy when indicated).
- Close the mucosal entry using hemostatic clips.
- Record procedure time, instrument exchanges, bleeding events, and forceps usage.
- Hybrid Knife (Erbe Elektromedizin GmbH)
- VIO 3 generator + ERBEJet 2 water-jet system
- Methylene-blue tinted saline
- Electrosurgical settings: ENDO CUT Q 2-3-3 for mucosal incision and myotomy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2026
CompletedFirst Submitted
Initial submission to the registry
May 4, 2026
CompletedFirst Posted
Study publicly available on registry
May 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2027
May 8, 2026
May 1, 2026
1.3 years
May 4, 2026
May 4, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:
1. Underwater preventive vessel coagulation, and 2. Conventional vessel coagulation under CO₂ insufflation.
60 minutes
Secondary Outcomes (9)
To compare composite forceps use (rescue + prophylactic) between groups.
60 minutes
To evaluate the frequency of prophylactic-only forceps use.
60 minutes
To compare total number of forceps applications per procedure.
60 minutes
To determine differences in intra-procedural bleeding episodes
60 minutes
To compare procedural efficiency (procedure time, number of instrument exchanges
60 minutes
- +4 more secondary outcomes
Study Arms (2)
Under Water Coagulation
Intervention Arm: Underwater Coagulation * Vessel coagulation performed entirely underwater using the Hybrid Knife. * SWIFT COAG: E3 (89 W) for POEM. * Physiological saline instilled to completely displace air around the target vessel.
Conventional Coagulation
Control Arm: Conventional Coagulation (CO₂ Setting) * Standard vessel isolation and coagulation under CO₂ insufflation. * SWIFT COAG: E3 (89 W) for POEM.
Interventions
Leverages water as a conductive medium. Preliminary evidence suggests that: 1. electrosurgical current in water is focalized at the interface of the vessel, 2. allowing a soft sealing of the vessel wall, 3. reducing the risk of vessel rupture or unintended deep thermal injury, 4. and potentially eliminating the need to convert to coagulation forceps.
Eligibility Criteria
120 (60 in each arm)
You may qualify if:
- Age ≥ 18 years
- Diagnosis of achalasia or esophageal motility disorder planned for POEM
- Ability to provide informed consent
You may not qualify if:
- Anticoagulant or antithrombotic therapy not safely stoppable
- Known coagulopathy or platelet disorder
- Esophageal/gastric varices
- Previous POEM or Heller's myotomy
- Prior treatment for same condition
- Inability or refusal to consent
- Visualized vessels smaller than the HK inner diameter (1.2 mm)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Asian Institute of Gastroenterology Hospital
Hyderabad, Telangana, 500082, India
Study Officials
- STUDY DIRECTOR
Mohan Dr Ramchandani, MD DM
Asian Institute of Gastroenterology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
May 4, 2026
First Posted
May 8, 2026
Study Start
February 1, 2026
Primary Completion (Estimated)
May 10, 2027
Study Completion (Estimated)
December 30, 2027
Last Updated
May 8, 2026
Record last verified: 2026-05